250+ investors that invest in your industry and stage
Transportation
Gaming
Community
Proptech
FinTech
Biotech
Climate
Marketplace
Artificial intelligence
Energy
Hardware
Media (entertainment)
EdTech
Consumer
Health Care
Impact
Enterprise
Agriculture (agtech)
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Web3
Publishing
Clean Energy
Sporting Goods
Oil and Gas
B2B
Education
Organic Food
Big Data
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Video Games
Financial Services
Payments
Photography
Celebrity
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Franchise
Blockchain
Legal
Android
Social Impact
Mobile
Google
Construction
Sports
Local
eSports
Enterprise Software
Email
Wellness
Social Network
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Platforms
Biotechnology
Medical Device
Wine And Spirits
Automotive
Crowdfunding
Social
CleanTech
InsurTech
SaaS
Software
Film
Theatre
Life Science
Non Profit
Qatar
New Zealand
United States
South Korea
Germany
Australia
India
United Kingdom
Ireland
Canada
Africa
Asia
LATAM
Europe
Oceania
Middle East
China
South Africa
Singapore
Brazil
Japan
Indonesia
Sri Lanka
Vietnam
Spain
Saudi Arabia
Argentina
Armenia
Austria
Bangladesh
Bahrain
Belarus
Bulgaria
Belgium
Bermuda
Chile
Cameroon
Switzerland
Colombia
Belize
Costa Rica
Denmark
Ecuador
Algeria
Czech Republic
Georgia
Estonia
Egypt
Ghana
Hong Kong
Ethiopia
Gibraltar
Faroe Islands
Greece
Finland
Croatia
France
Hungary
Barbados
Kuwait
Italy
Jersey
Israel
Lebanon
Cambodia
Kenya
Cayman Islands
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Mali
Morocco
Norway
Malaysia
Mexico
Panama
Malta
Mauritius
Peru
Philippines
Nicaragua
Pakistan
Poland
Russian Federation
Romania
Sweden
Rwanda
Serbia
Seychelles
Turkey
Togo
Puerto Rico
Slovenia
Sierra Leone
San Marino
Senegal
Tunisia
Tanzania
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Thailand
Taiwan
Ukraine
Uruguay
Zimbabwe
Venezuela
Portugal
Azerbaijan
Bahamas
Guatemala
Iraq
Iceland
Namibia
Nigeria
United Arab Emirates
Honduras
Bolivia
Isle of Man
Luxembourg
Cyprus
Latvia
Oman
Angel investors
VC Funds
All investors
Download Find emails Save list

Top 50 Medical VC (Venture Capital) Funds in Switzerland in October 2023

A list of 50 VC (Venture Capital) funds that invest in Medical startups based in Switzerland. We rank investors based on the number of investments they made in Medical companies from Switzerland. We update this investor list every month.

Top 50 Medical VC (Venture Capital) Funds in Switzerland in October 2023

Investor Medical Switzerland investments
Zürcher Kantonal Bank 17
Verve Ventures 13
Foundation for Technological Innovation (FIT) 9
BioMedPartners 6
BlueOcean Ventures 5
Swisscom Ventures 5
StartAngels Network 5
4FO Ventures 4
New Enterprise Associates 4
Versant Ventures 4
GoBeyond 4
Polytech Ventures 4
Sunstone Life Science Ventures 4
Eclosion SA 4
Sofinnova Partners 4
Fongit Seed Invest 4
3wVentures 4
Wingman Ventures 3
Inserm Transfert Initiative 3
Bernina BioInvest 3
EIT Health 3
Schroder Adveq 3
Index Ventures 3
M Ventures 3
EQT life science 3
Zühlke Ventures AG 3
VINCI CAPITAL 3
Gilde Healthcare 3
OrbiMed 3
Alpana Ventures 3
Broadview Ventures 3
Endeavour Vision 3
Viva BioInnovator 2
Boundary Holding 2
The William K. Warren Foundation 2
SICTIC 2
Innosuisse 2
Baszucki Group 2
ORTHO INNOVATIONS 2
VI Partners 2
Bpifrance 2
4See Ventures 2
Ysios Capital 2
Boehringer Ingelheim Venture Fund 2
Novartis Venture Fund 2
EVA Basel 2
Healthspan Capital 2
Grazia Equity 2
Lichtsteiner Foundation 2
R42 Group 2

Get 300+ niche investors in 2 minutes.

Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.

Find investors — It's Free!

Trusted by 21,000+ founders from:

Y Combinator Techstars Antler Pioneer On Deck
Investor list
Zürcher Kantonal Bank
VC Fund · Zürich, Zurich, Switzerland · 17 investments in the past 12 months

Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.

Show more...

Investment focus

  • Health Care, Medical Device, Biotechnology
  • Seed, Series A, Funding Round
  • Switzerland, Japan, Germany

Portfolio highlights

  • Helio — Carbon Aware Cloud Computing.
  • Tune Insight — Tune Insight orchestrates secure collaborations on sensitive data between multiple organizations to extract collective insights.
  • Nagi Bioscience — Enabling small organisms testing to any lab. Unleash unique datapoints efficiently at a high-throughput rate.
Show more investments...

Verve Ventures
VC Fund · Zug, Zug, Switzerland · 16 investments in the past 12 months

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Show more...

Investment focus

  • Health Care, Software, Biotechnology
  • Series A, Seed, Series B
  • Switzerland, Germany, France

Portfolio highlights

  • MedTrace Pharma — MedTrace develops a hardware platform (MT-100) that automates the production and injection of the gold standard tracer 15O-water into the patient. MedTrace also develops an analytical software platform to interpret the results from the PET scanner.By use of 15O-water, doctors will increase sensitivity in the analysis of the patient while at thesame time increasing patient throughput up to a factor of 4 compared to today's clinical workhorse.
  • Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
  • Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Show more investments...

Foundation for Technological Innovation (FIT)
VC Fund · Lausanne, Vaud, Switzerland · 7 investments in the past 12 months

The Foundation for Technological Innovation (FIT) has been helping startups since 1994, encourages entrepreneurship & supports innovation.

Show more...

Investment focus

  • Health Care, Biotechnology, Information Technology
  • Debt Financing, Grant, Seed
  • Switzerland, France

Portfolio highlights

  • Voltiris — Voltiris filters natural sunlight to transmit it to plants and recycle the "wasted" sunlight into green electricity.
  • PeriVision — Perivision combines artificial intelligence, virtual reality, and the cloud to build the next generation of systems to understand visual function. The company's systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
  • AdVentura Works — AdVentura Works is a Swiss technology company offering material handing as a service to logistics and industrial companies
Show more investments...

BioMedPartners
VC Fund · Basel, Basel-Stadt, Switzerland

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • Switzerland, Germany, France

Portfolio highlights

  • Tricares — TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
Show more investments...

BlueOcean Ventures
VC Fund · Plan-les-ouates, Geneve, Switzerland

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Show more...

Investment focus

  • Health Care, Medical, Personal Health
  • Series A, Seed, Series B
  • Switzerland, India, France

Portfolio highlights

  • Ava — Ava makes it easy to gain a profound and accurate understanding of your cycle and health—empowering you to make informed choices for your life. Because we believe every woman deserves greater control over her wellbeing, and the tools to maximize her physical and emotional potential.
  • CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
  • 99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors
Show more investments...

Swisscom Ventures
VC Fund · Zürich, Zurich, Switzerland · 7 investments in the past 12 months

Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.

Show more...

Investment focus

  • Software, SaaS, Information Technology
  • Funding Round, Series B, Series A
  • Switzerland, United States, France

Portfolio highlights

  • viboo — viboo offers self-learning predictive control on the basis of physics-informed Machine Learning as a cloud service to smart-thermostat and building automation companies.
  • ecoRobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
  • AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
Show more investments...

StartAngels Network
VC Fund · Zürich, Zurich, Switzerland · 2 investments in the past 12 months

StartAngels Network is a Zurich-based angel investment firm that provides investment consulting services.

Show more...

Investment focus

  • Medical Device, Health Care, Medical
  • Seed, Series A, Series B
  • Switzerland, Brazil

Portfolio highlights

  • Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
  • Pipra — PIPRA AG (Pre-Interventional Preventive Risk assessment) is developing a cutting-edge AI-based pre-operative test to assess a patient's risk of suffering from cognitive disorders after surgery.
  • Hylomorph — Hylomorph is a clinical-stage medical device company developing innovative materials designed to transform the biocompatibility of implantable medical devices.
Show more investments...

4FO Ventures
VC Fund · Luxembourg, Luxembourg, Luxembourg · 1 investment in the past 12 months

4FO Ventures

Show more...

Investment focus

  • Artificial Intelligence, Health Care, Medical
  • Series A, Seed, Series B
  • Switzerland

Portfolio highlights

  • ecoRobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
  • ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.
  • Giotto.ai — We complement modern machine learning with topology, the science of shapes. Increased interpretability and robustness are the direct benefits of this novel approach.Our first product, Giotto Compliance (compliance.giotto.ai), facilitates the consolidation of clinical evidence in the context of regulatory processes by leveraging proprietary NLPtechnology. This state-of-the-art AI software allows significant time and cost savings for medical device companies and medical writers.
Show more investments...

New Enterprise Associates
VC Fund · Menlo Park, California, United States · 47 investments in the past 12 months

New Enterprise Associates, Inc. is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’slifecycle, from the seed stage through IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.

Show more...

Investment focus

  • Software, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, India, China

Portfolio highlights

  • Meeno — Meeno is a relationship mentoring app powered by generative AI
  • Rocket.Chat — Explore Rocket.Chat, where we put data privacy into every conversation and enable teams to collaborate seamlessly.
  • Pulumi — Pulumi's open source infrastructure as code SDK enables you to create, deploy, and manage infrastructure on any cloud, using your favorite languages.
Show more investments...

Versant Ventures
VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada

Portfolio highlights

  • Kate Therapeutics — Kate Therapeutics is a patient-focused biotechnology company developing AAV-based gene therapies to treat genetically defined muscle and heart diseases.
  • Nexo Therapeutics — Nexo Therapeutics is a small molecule oncology company dedicated to the discovery and development of new drugs for cancer patients who currently lack meaningful therapies.
  • Tentarix Biotherapeutics — Tentarix creates innovative protein therapeutics with uniquely combined bioactivities that leverage synthetic biology. The company develops a protein engineering platform designed for multispecific therapies.
Show more investments...

GoBeyond
VC Fund · Zürich, Zurich, Switzerland · 1 investment in the past 12 months

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Show more...

Investment focus

  • Information Technology, Medical, Software
  • Funding Round, Seed, Series A
  • Switzerland, Germany, United Kingdom

Portfolio highlights

  • LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
  • AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
  • Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.
Show more investments...

Polytech Ventures
VC Fund · Lausanne, Vaud, Switzerland

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Show more...

Investment focus

  • Financial Services, FinTech, Software
  • Seed, Series A, Funding Round
  • Switzerland, United States, Spain

Portfolio highlights

  • yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
  • Relai — Relai is a Bitcoin investment app that allows anyone to buy bitcoin within one minutes or set up an automated savings plan.
  • Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle
Show more investments...

Sunstone Life Science Ventures
VC Fund · Copenhagen, Hovedstaden, Denmark · 2 investments in the past 12 months

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Funding Round, Series B, Series A
  • Denmark, Sweden, Switzerland

Portfolio highlights

  • Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
  • TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
Show more investments...

Eclosion SA
VC Fund · Geneva, Geneve, Switzerland

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Show more...

Investment focus

  • Biotechnology, Pharmaceutical, Health Care
  • Seed, Series C, Funding Round
  • Switzerland

Portfolio highlights

  • KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
  • Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
  • MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases
Show more investments...

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 21 investments in the past 12 months

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • France, United States, United Kingdom

Portfolio highlights

  • Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
  • Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
  • Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Show more investments...

Fongit Seed Invest
VC Fund · Plan-les-ouates, Geneve, Switzerland

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Show more...

Investment focus

  • Health Care, Medical, Biotechnology
  • Seed, Series A, Series B
  • Switzerland

Portfolio highlights

  • EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
  • Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
  • Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.
Show more investments...

3wVentures
VC Fund · Herisau, Ausser-Rhoden, Switzerland

3wVentures provides seed money and venture capital to international internet startups. As they focus on early stage projects and prototypes, our investments and co-investments target a volume of up to USD 250,000.

Show more...

Investment focus

  • Software, Health Care, Information Technology
  • Seed, Angel, Series A
  • Switzerland, Spain, Austria

Portfolio highlights

  • Abionic — Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergyprofiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection.Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.Abionic SA is a privately owned high-tech company and is strongly supported by the Swiss Federal Institute of Technology of Lausanne (EPFL), The Canton of Vaud and Venturelab.Abionic was founded by former scientists from the biomedical optics laboratory (LOB) at EPFL. Its headquarters are located in Lausanne, Switzerland.Abionic appreciates the support it has received from:
  • GUURU — Convert undecided shoppers into confident buyers with instant, authentic advice from your expert community.
  • Pregnolia — Pregnolia ensures that every woman can have a happy, healthy and informed pregnancy until term. Their team knows that the existing research about preterm birth assessment is very promising, but this alone does not guarantee success. Sabrina, Francisco and Annette are highly committed to develop the commercial version of the device, complete theclinical trial, follow the regulatory roadmap and execute on their business vision to successfully support gynaecologists in improving the preterm birth risk assessment and birth management.
Show more investments...

Wingman Ventures
VC Fund · Zürich, Zurich, Switzerland · 11 investments in the past 12 months

We dedicate our know-how, experience and energy to the new generation of startup founders, helping them navigate the skies on their way to success.

Show more...

Investment focus

  • Software, Artificial Intelligence, SaaS
  • Pre-Seed, Seed, Series A
  • Switzerland, United Kingdom

Portfolio highlights

  • Ascento — Secure, maintain, and inspect outdoor assets by reducing the intervention times and augmenting data capturing capability.
  • Tune Insight — Tune Insight orchestrates secure collaborations on sensitive data between multiple organizations to extract collective insights.
  • Saeki Robotics — Building the future of autonomous robotic manufacturing.
Show more investments...

Inserm Transfert Initiative
VC Fund · Paris, Ile-de-France, France

Inserm Transfert Initiative is a seed stage life science vehicle currently managing about €4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.

Show more...

Investment focus

  • Biotechnology, Medical, Health Care
  • Series A, Series B, Seed
  • France, Switzerland, United States

Portfolio highlights

  • Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
  • VectivBio — VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and theirfamilies, not just provide an incremental improvement or benefit over the standard-of-care.It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
  • Aelis Farma — Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways.Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.
Show more investments...

Bernina BioInvest
VC Fund · Zug, Zug, Switzerland

Bernina BioInvest is an investment Firm.

Show more...

Investment focus

  • Biotechnology, Health Care, Biopharma
  • Seed, Series A, Series B
  • Switzerland

Portfolio highlights

  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
  • Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
Show more investments...

EIT Health
VC Fund · Munich, Bayern, Germany · 1 investment in the past 12 months

EIT Health is a network of best-in-class health innovators backed by the EU. We deliver solutions to enable European citizens to live longer, healthier lives.

Show more...

Investment focus

  • Health Care, Medical Device, Medical
  • Grant, Pre-Seed, Seed
  • United Kingdom, Spain, Ireland

Portfolio highlights

  • Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
  • ZiO Health — ZiO Health develops multi-functional electronic devices for measuring, testing and detecting the molecular composition of chemical and biological substances for the presence, absence, or quantity of target molecules.
  • Nanordica Medical — Nanordica Medical develops novel nanoparticle-based antibacterial wound care products.
Show more investments...

Schroder Adveq
VC Fund · Zürich, Zurich, Switzerland

Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.

Show more...

Investment focus

  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • Switzerland, United States, India

Portfolio highlights

  • Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Show more investments...

Index Ventures
VC Fund · San Francisco, California, United States · 32 investments in the past 12 months

Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.

Show more...

Investment focus

  • Software, E-Commerce, Internet
  • Series A, Series B, Seed
  • United States, United Kingdom, France

Portfolio highlights

  • Apron — Sort, pay and reconcile your invoices in seconds.
  • Worldover — Cosmetic compliance made simple
  • Class Companion — Class Companion is a new AI technology that allows professors to provide students with immediate, individualized feedback.
Show more investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 17 investments in the past 12 months

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Switzerland, United Kingdom

Portfolio highlights

  • CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
  • BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
  • Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Show more investments...

EQT life science
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 6 investments in the past 12 months

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Show more...

Investment focus

  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, The Netherlands, Switzerland

Portfolio highlights

  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Show more investments...

Zühlke Ventures AG
VC Fund · Schlieren, Zurich, Switzerland

Zühlke Ventures AG is a venture capital arm of Zühlke Technology Group AG specializing in financing of start-ups at an early stage and providing growth capital. It seeks to invest in the technology and medical devices companies. It typically invests in German-speaking Europe and Great Britain.

Show more...

Investment focus

  • Health Care, Medical Device, Biotechnology
  • Series A, Seed, Series B
  • Switzerland, Sweden, United States

Portfolio highlights

  • Evismo — Evismo provides diagnostics services in Switzerland
  • Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
  • Flow Neuroscience — Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry.
Show more investments...

VINCI CAPITAL
VC Fund · Lausanne, Vaud, Switzerland

Vinci Capital is a leading Swiss private equity firm with over MCHF 200 under management. Since 1998 they have provided equity to over 30 Swiss technology and industrial companies to finance innovation, growth and succession-buyouts.Their investment team capitalizes on 40 years of cumulated experience in private equity and a solid operationalbackground in growth, turn-around, consolidation, IPOs and M&A situations.

Show more...

Investment focus

  • Medical, Health Care, Biotechnology
  • Series A, Series B, Funding Round
  • Switzerland, Germany

Portfolio highlights

  • Anergis — Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne inSwitzerland.
  • SENSIMED — Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.
  • Beqom — beqom is a Total Compensation Management Software Solution focused exclusively on managing compensation & performance for HR & Sales.
Show more investments...

Gilde Healthcare
VC Fund · Utrecht, Utrecht, The Netherlands · 6 investments in the past 12 months

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Series C, Series B, Series A
  • United States, The Netherlands, Germany

Portfolio highlights

  • FIRE1 — FIRE1 and is based in Dublin, Ireland, will focus on developing novel therapeutic devices.
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • GT Medical Technologies — At GT Medical Technologies, our purpose is Improving the Lives of Patients with Brain Tumors. GammaTile Therapy is Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors.
Show more investments...

OrbiMed
VC Fund · New York, New York, United States · 38 investments in the past 12 months

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Show more...

Investment focus

  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, China, Israel

Portfolio highlights

  • Evozyne — We have a new way of thinking about proteins. We've uncovered Nature's hidden rules to build Natural Machines. With our partners, we are changing the world.
  • Adela — Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.
  • Iambic Therapeutics — Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need.
Show more investments...

Alpana Ventures
VC Fund · Geneva, Geneve, Switzerland · 5 investments in the past 12 months

Alpana Ventures is a Swiss VC focusing on digital transformation.Since 2016 we backed 45 founder teams with 3 Funds, supporting them in their journey towards a positive impact.Committed to value creation, we discover deep tech solutions in Switzerland, Europe and the US.We invest to embed them into innovative business models and back them tobecome global market leaders.Applying ESG criteria, our portfolio companies help create a more sustainable future.

Show more...

Investment focus

  • Software, FinTech, Information Technology
  • Seed, Series A, Series B
  • United States, Switzerland, Germany

Portfolio highlights

  • Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
  • Nezasa — Nezasa’s travel booking solution empowers travel brands globally to combine all planning and booking related actions into one seamless end-to-end experience.Our tools, enable to plan and book any type of multi-product or multi-stop itinerary.TripBuilder Hyper-personalised packaging Real-time planning and booking of personalised itinerariesPowerful, easy to use and very interactive Deep integration possibilities into existing fulfilment landscapes Enterprise-grade, proven with large TO customersTripBooster Hyper-personalised In-Destination Upselling The extension of TripBuilder’s power throughout the entire travel lifecycle The perfect travel companion Seamless purchasing of perfectly fitting additional products Smart upselling recommendation, available in both a push and pull mode
  • Tinamu — Tinamu Labs has developed a technology that converts commercially available drones into camera equipment reaching professional standards.
Show more investments...

Broadview Ventures
VC Fund · Boston, Massachusetts, United States · 2 investments in the past 12 months

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

Show more...

Investment focus

  • Health Care, Biotechnology, Medical Device
  • Series A, Seed, Debt Financing
  • United States, Israel, Denmark

Portfolio highlights

  • Nyra Medical — MitraPlug has created a catheter-plug technology for repairing a leaky mitral valve in the heart.This adjustable device needs only a two-inch surgical incision and can be inserted directly into the heart. Then the cardiologist can use the catheter to adjust the size and position of the plug to correct the leakage. When correctly fitted, thecatheter is removed, and the incision is closed, leaving only a small scar.
  • RapidPulse — RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
  • Cardiosense — Cardiosense offers a physiological waveform AI platform to develop predictive biomarkers for the detection and treatment of disease. Its platform leverages multi-modal sensors and industry-leading AI to develop predictive biomarkers for the detection and treatment of disease.
Show more investments...

Endeavour Vision
VC Fund · Geneva, Geneve, Switzerland · 4 investments in the past 12 months

Endeavour Vision is a venture capital and growth equity firm investing in transformative healthcare technologies.

Show more...

Investment focus

  • Health Care, Medical, Biotechnology
  • Series C, Series B, Series A
  • United States, Switzerland, France

Portfolio highlights

  • Venture Med Group — VentureMed Group (VMG) designs, develops and markets innovative medical devices which enable interventionalists to cost effectively treat peripheral artery diseases and improve the lives of their patients.Founded by physicians who understand the clinical, medical and financial demands in today’s healthcare environment, VMG creates truly costeffective solutions. Their flagship product, the FLEX Scoring Catheter enables providers to reduce expensive inventory costs while offering the interventionalist more treatment options from a single device.
  • Miach Orthopaedics — Miach Orthopaedics is a medical device company that develops bio-engineered surgical implants to facilitate new tissue growth. The company's product is the Bridge-Enhanced ACL Repair technology as a viable alternative to conventional ACL reconstruction for patients who have withstand an anterior cruciate ligament injury.Miach Orthopaedicswas founded on 2016 and is headquartered in Westborough, Massachusetts.
  • Relievant Medsystems — Relievant's mission is to provide patients with low risk therapy that can alleviate their back pain.
Show more investments...

Viva BioInnovator
VC Fund · Shanghai, Shanghai, China · 1 investment in the past 12 months

Viva BioInnovator (VBI) is the specialized investment and incubation arm of Viva Biotech Holdings. We focus on the initial creation and development of biotech startups across all indications and drug types. During the early stages of drug discovery, we can nurture and accelerate a startup's growth from idea to clinical program. VBI'sunique investment and incubation model started out of necessity in 2014. Our roots are in drug discovery services, where we operate world-leading and proprietary drug discovery platforms. While serving big pharma customers from around the globe, we came to realize the huge demand from many entrepreneurs who have great ideas but cannot receive funding to advance their plan due to lack of data. We saw the value in many of these innovative ideas and provided our CRO drug discovery services, operational support, and monetary backing to help these creative scientists embark on the "0 to 1"​ transformation. This spark launched our "equity for service (EFS)"​ investment and incubation model. VBI is based in Shanghai, with an office in Boston and personnel in California. As of early 2019, VBI has invested in over 30 companies out of the hundreds of proposals submitted for review and we plan to invest at a rapid pace in the years to come. The majority of our current portfolio companies are US based, but we are open to proposals globally and are excited to see new ideas that fit our investment strategy. If you would like to learn more about us, please visit: www.vivabioinnovator.com Or send an email to innovation@vivabiotech.com If you would like to learn more about our parent company, Viva Biotech, please visit: www.vivabiotech.com

Show more...

Investment focus

  • Biotechnology, Health Care, Therapeutics
  • Seed, Series A, Series B
  • United States, Canada, Switzerland

Portfolio highlights

  • ArrePath — ArrePath is an anti-infective drug discovery company addressing the global health challenge of drug resistant infections.
  • Deka Biosciences — Deka BioSciences, Inc. is committed to developing and delivering life-changing medicines to patients with cancer and inflammatory diseases.
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Show more investments...

Boundary Holding
VC Fund · Luxembourg, Luxembourg, Belgium

Boundary Holding is a European deep tech investment firm with presence in Luxembourg and France that invests in technologies enabling 4th industrial revolution.

Show more...

Investment focus

  • Drones, Robotics, Artificial Intelligence
  • Seed, Series A, Series B
  • Switzerland, India, France

Portfolio highlights

  • Aero41 — Aero41 is developing a drone entirely dedicated to crop protection, a flexible and intelligent platform that will integrate AI and collect data to make crop protection more and more eco-responsible while being effective to ensure the necessary yields.
  • Neo Medical — Neo aims at transforming the current approach to spinal surgery by providing a unique answer to the worldwide strive for healthcare cost optimization through efficient, versatile and high quality systems.
  • Remidio Innovative Solutions — Remidio is engaged in designing & developing Smart, Innovative & Disruptive Imaging Technologies in Vision Care, using a product development approach called “Design Thinking”.As part of the Design Thinking process, Remidio takes into account different facets of a customer’s experience with a product, as part of its overall productdesign approach, with the intent of inventing a new customer experience with the product.Customers can be an amazing resource to glean insight and understanding, but they are generally not able to articulate their latent and anticipated needs. Remidio hence focuses on making quick functional prototypes, that can then be given to the customer to understand these latent needs while observing their use of the prototypes.Founded by professionals with a passion for product innovation, Remidio is currently focussed on creating game changing products and solutions in the ophthalmology space.We look at constraints posed by a developing nation context- infrastructure, skilled resources and affordable pricing as an opportunity to innovate.We bring to market very high quality products that are reliable and extremely simple to use.
Show more investments...

The William K. Warren Foundation
VC Fund · 2 investments in the past 12 months

The William K. Warren Foundation focuses on people and aims to improve the human condition on earth as a response to and in thanksgiving.The foundation's goal is to make medical care available to all patients utilizing Saint Francis Health System, and to this end, it annually supports various medical programs. In addition to the hospitalsand clinics, the foundation created The William K. Warren Medical Research Centre in 1973, which provides funds to medical investigators who participate in advanced medical research and creates environments that allow for the best possible delivery of care.

Show more...

Investment focus

  • Machine Learning, Health Care, Artificial Intelligence
  • Seed, Series A, Series B
  • United States, Switzerland

Portfolio highlights

  • KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
  • Spring Health — Eliminating barriers to mental healthcare. Clinically-proven technology with world-class providers to deliver precisely what your employees need.
  • iRecommend Software™ — iRecommend Software™ develops intelligent business solutions utilizing artificial intelligence (AI), machine learning, and dynamic data modeling.In a consumer-driven economy, businesses across all industries, are facing the challenge to remain relevant and provide highly personalized products and services.iRecommend's leading solution,Recommendation360™ is a recommendation engine with applications across multiple industries, including recruiting, real estate, retail/e-commerce, entertainment, travel, government, and healthcare. These industry-specific solutions enable businesses to generate hyper-personalized recommendations of products and services for their customers. Recommendation360's proprietary technology rapidly aggregates and analyzes millions of data points from the public domain to provide the right products or services to the right person at the right time. Headquartered in Tulsa, Oklahoma with offices in Oklahoma City, New York, San Francisco, London, and Dubai.
Show more investments...

SICTIC
VC Fund · Zürich, Zurich, Switzerland · 6 investments in the past 12 months

How to Invest in Swiss Startups That Last The Investor community of the Swiss ICT Investor Club (SICTIC) helped to fund to more than 160 Swiss tech startups to date. While doing so, they learned a lot about what to watch out for and how to foster success. Read more Get your FREE angel handbook

Show more...

Investment focus

  • Software, Information Technology, Artificial Intelligence
  • Seed, Pre-Seed, Series A
  • Switzerland, Germany, United Kingdom

Portfolio highlights

  • Axom — Axom automating visual inspection through image analysis in the healthcare industry.
  • Gaia Tech — Gaia Technologies turns agricultural sidestreams into high-value ingredients for cosmetics, food, and feed manufacturers.
  • PeriVision — Perivision combines artificial intelligence, virtual reality, and the cloud to build the next generation of systems to understand visual function. The company's systems improve workflow efficiency in practices and hospitals and provide deeper clinical insight into eye diseases.
Show more investments...

Innosuisse
VC Fund · Berne, Bern, Switzerland · 4 investments in the past 12 months

Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland.

Show more...

Investment focus

  • Health Care, Biotechnology, Medical Device
  • Grant, Pre-Seed, Seed
  • Switzerland, United States, Taiwan

Portfolio highlights

  • Pelt8 — Pelt8 enables climate action through the platform with scalable processes and controls to collect sustainability-related data in an easy and traceable way.
  • Atinary — Atinary is an end-to-end AI, machine learning, robotics, and cloud computing technology platform for digitizing R&D operations.
  • Ascento — Secure, maintain, and inspect outdoor assets by reducing the intervention times and augmenting data capturing capability.
Show more investments...

Baszucki Group
VC Fund · 2 investments in the past 12 months

Baszucki Group directs resources toward the greater good through mission-driven investments that improve human health, governance, and the health of our planet.

Show more...

Investment focus

  • Medical, Health Care, Biotechnology
  • Seed
  • Switzerland

Portfolio highlights

  • KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Show more investments...

ORTHO INNOVATIONS
VC Fund · Phoenix, Arizona, United States · 2 investments in the past 12 months

Ortho Innovations is a manufacturer of orthopedic products. The company's products are the elbow brace, knee brace, hyperflexion elbow, wrist, flexion-extension, wrist pronation, supination, and hip abduction orthosis.

Show more...

Investment focus

  • Medical, Health Care, Biotechnology
  • Seed
  • Switzerland

Portfolio highlights

  • KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
Show more investments...

VI Partners
VC Fund · Altendorf, Schwyz, Switzerland · 3 investments in the past 12 months

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Show more...

Investment focus

  • Health Care, Biotechnology, Medical Device
  • Series A, Series C, Series B
  • Switzerland, Germany, United States

Portfolio highlights

  • Vara — Vara develops a breast cancer screening platform powered by AI for radiologists, allowing them to focus on finding cancer early. While we provide. Vara also provides remote mammography reading services to those that lack the radiologists. Vara's mission is to make affordable diagnostics available all over the world by designing machinelearning-powered workflows that users love to work with.
  • Oculis — The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME(diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. Furthermore, the technique has been demonstrated to allow diseases at the anterior part of the eye to be treated with a reduced number of topical applications compared to conventional eye-drops.
  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
Show more investments...

Bpifrance
VC Fund · Maisons-alfort, Ile-de-France, France · 117 investments in the past 12 months

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Show more...

Investment focus

  • Software, Health Care, Information Technology
  • Funding Round, Seed, Series A
  • France, United States, Switzerland

Portfolio highlights

  • Nonna Lab — Make the Most. Le laboratoire qui vous rend la vie meilleure.
  • Altior — Altior is an IT company that offers cloud industrial management software and ERP solution.
  • Umiami — Umiami Technologies is a leader in plant-based meat. Our proprietary technology allows us to create clean-label and incredibly tasty foods.
Show more investments...

4See Ventures
VC Fund · Secheron, Geneve, Switzerland

4see ventures is a Swiss venture capital firm investing in exceptional entrepreneurs who are defining the future. We focus on real game-changers in their industries who are having a positive impact on society.

Show more...

Investment focus

  • Medical, Health Care, Security
  • Seed, Series C
  • Switzerland, Israel

Portfolio highlights

  • CYSEC — Secure your sensitive data in the cloud and in the edge with ARCA Trusted OS and open the door to innovation with confidential computing.
  • keepMED — keepMED develops a device for treatment of Obstructive Sleep Apnea, a disorder characterized by repetitive episodes of upper airway obstruction that occur during sleep.
  • HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Show more investments...

Ysios Capital
VC Fund · San Sebastian, Pais Vasco, Spain · 3 investments in the past 12 months

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Show more...

Investment focus

  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • Spain, United States, Switzerland

Portfolio highlights

  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Show more investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 3 investments in the past 12 months

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Show more...

Investment focus

  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Germany, Belgium

Portfolio highlights

  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Show more investments...

Novartis Venture Fund
VC Fund · Basel, Basel-Stadt, Switzerland · 5 investments in the past 12 months

Our primary focus is on the development of novel therapeutics and platforms. We balance the therapeutic focus with investments in medical devices, diagnostics or drug delivery systems. In our investments we look for unmet need and clinical impact, novel proprietary science and understanding of mechanism, management and board experience and capitalefficiency in the program.We prefer to have our initial investment at the early stage to build the company and follow with additional investment in pace with the company:tm:s progress. We continue our approach of larger focused investments and anticipate total investments up to USD 30 to 50 mio per company over its life, but it can be as little as 100'000 USD to get started. We will increase our activities to lead or co-lead deals further and remain open to participate in larger syndicates. SectorsNew therapeutics & platformsMedical devices/implantsDiagnostics/biomarkersDrug delivery/biopolymersGeographyUSA/CanadaEuropeSwitzerlandAsia/Pacific

Show more...

Investment focus

  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom

Portfolio highlights

  • Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
  • Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
  • Mediar Therapeutics — Mediar Therapeutics is a preclinical stage biotechnology company developing antibody-based therapeutics to halt fibrosis in a variety of organ systems, including lung, liver, kidney, and skin.
Show more investments...

EVA Basel
VC Fund · Basel, Basel-Stadt, Switzerland

EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.

Show more...

Investment focus

  • Biotechnology, Medical Device, Medical
  • Seed, Series A
  • Switzerland

Portfolio highlights

  • AOT - Advanced Osteotomy Tools — AOT AG is a privately owned Swiss Robotic Surgery company, which spun out of the University Hospital and the University Basel (Switzerland) in 2011 and was first funded in 2012. The company is dedicated to the development, manufacturing and sales of medical devices for osteotomy pursuing the vision of contact-free bone surgery using laser,robotics and navigation systems to re-invent bone surgery (osteotomy).
  • POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
  • Memo Therapeutics — Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations.
Show more investments...

Healthspan Capital
VC Fund · El Cerrito, California, United States · 2 investments in the past 12 months

Healthspan Capital is an early-stage longevity venture capital firm that invests in biotechnology startups developing therapies to slow or reverse aging.

Show more...

Investment focus

  • Health Care, Medical, Software
  • Seed
  • Germany, Switzerland

Portfolio highlights

  • KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
  • Molecule — Molecule is a collaborative platform, where stakeholders in drug development work together to accelerate the process of bringing novel therapeutics to patients. We connect leading researchers to investment opportunities by turning intellectual property and its development into a liquid and easily investable asset.
Show more investments...

Grazia Equity
VC Fund · Stuttgart, Baden-Wurttemberg, Germany · 1 investment in the past 12 months

Grazia Equity is a venture Capital firm investing in innovative, technology driven startups with high potential.Based in Stuttgart (Germany), Grazia has been supporting a large number of mostly young companies, often from their foundation to the Initial Public Offering or eventual sale. In contrast to other venture capital firms, theypredominantly work with their own capital that they invest as entrepreneurs.

Show more...

Investment focus

  • Internet, E-Commerce, Biotechnology
  • Series A, Seed, Series B
  • Germany, United States, Switzerland

Portfolio highlights

  • VYTAL — Start the Packaging Revolution! We are offering smart & reusable To-Go Packaging-as-a-Service to gastronomy clients & consumers.In Germany the consumption of take-away, convenience and delivery food & drinks is responsible for about 281 kilotons of single-use packaging waste for immediate consumption and is growing at double digitrates. Most of the time, To-Go food containers, snack boxes or coffee cups have a very short life-span of only 30 minutes after which they are tossed into trash (or litter parks, beaches & the ocean). This is not only a giant waste of economic resources as each single use costs between 15 and up to 0,60€ for a stable bowl/box with a lid. It is a horrendous waste of environmental resources (wood, water, crude oil, metals & energy) that are used to produce this packaging. Therefore, a single use packaging not weighing more than 30 grams can easily come with an ecological backpack of more than 8 kilograms when taking into account all the resources used in production (material intensities taken from Wuppertal Institute for Climate, Environment and Energy). Looking at GHG emissions, the picture is similarly bleak: Using CO2 emission factors and the detailed material mix of the single-use packaging waste analyzed by NABU (German Nature and Biodiversity Conservation Union), the 281 thousand tons waste from To-Go consumption generated around 556 thousand tons of CO2 or the equivalent of 195k passenger cars per year (assuming an average distance travelled of 15,000km). With the expected rise of take-away, convenience and delivery food, the related emissions are expected to increase at double digit rates as waste volume is expected to increase and as we saw a shift to plastics relative to cardboard or other materials. While there is a growing awareness of the problem, especially in Germany, there is no scalable solution yet and the commonly used alternative of nature-based & ‘biodegradable’ materials like bagasse or PLA also require many resources for production & transport, and have to be incinerated or go to landfill after use as there is currently no way to compost them.
  • ZAGENO — ZAGENO is a multi-vendor, online marketplace of life science products which, by simplifying the procurement process, saves more time for science.
  • Hypatos — Manual document processing is a major cost driver. Hypatos' deep learning tech automates complex document processing tasks. Make back office more efficient!
Show more investments...

Lichtsteiner Foundation
VC Fund · Berne, Bern, Switzerland

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Show more...

Investment focus

  • Medical, Health Care, Biotechnology
  • Seed, Series A
  • Switzerland

Portfolio highlights

  • Microcaps — Microcaps provides a novel solution to encapsulate ingredients naturally, protect them an enhance them with high-end appearence
  • Healios AG — Healios CTMS provides the Digital Biomarker based technology and digital validation scales to improve and streamline research and clinical practice.
  • MUVON Therapeutics — Muvon Therapeutics platform helps women with urinary incontinence and treats diseases based on skeletal muscle degradation, supporting them in their commitment to living a healthy life. The company's mode of contact is by mail, phone, and physical address.
Show more investments...

R42 Group
VC Fund · Stanford, California, United States · 3 investments in the past 12 months

R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.

Show more...

Investment focus

  • Biotechnology, Health Care, Information Technology
  • Seed, Pre-Seed, Series A
  • United Kingdom, United States, Austria

Portfolio highlights

  • Silveray — Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.
  • KetoSwiss — KetoSwiss is a Swiss-based BioTech startup that strives to bring ketone bodies back into the modern world to combat diseases. It develops and clinically tests a novel nutraceutical/medical food for the dietary preventive therapy of higher-frequency migraines and possibly other related neurological diseases characterized by a metabolicdysfunction (such as Alzheimer's disease). KetoSwiss is headquartered at the Technologie Park Basel, in Basel Switzerland, where it is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and s world-leading biotech-startup-ecosystem.
  • WiseWorks — AI-Powered Communications Intelligence for Financial Institutions
Show more investments...
Investors by industry
Investors by country
VC (Venture Capital) Funds in Switzerland by industry

Close your round

Find who invests in your industry, stage, and region in our 200k+ database with AI-powered matching.

Find investors — It's Free!

Join 21,000+ founders from:

Y Combinator Techstars Antler Pioneer On Deck